Morgan Joseph Reiterates a 'Buy' on Immunogen (IMGN); Encouraging Incremental Data From IMGN901 and SAR3419
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Morgan Joseph reiterates a 'Buy' on Immunogen Inc. (NASDAQ: IMGN), PT $16.
Morgan analyst said, "Encouraging new data on IMGN901 in a Phase I multiple myeloma study was reported this weekend at ASCO. Specifically, 13 of 18 patients were evaluable in the combination Phase I study evaluating the combination of IMGN901 with Revlimid and dexamethasone. Objective responses were seen in 8 of the 13 patients evaluated in the study. Most patients had been progressing on 2-3 prior regimens of therapy, which are considered industry standard. Patients were evaluated in three dose levels: 75, 90, and 112 mg/m2 given weekly for 3 weeks in a 4 week cycle. In the two higher doses, dose reduction was required due to peripheral neuropathy. Despite dose reductions, several patients continued to respond while neuropathy improved. We are now more confident that IMGN901 could be an approved oncology drug."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $11.76 yesterday.
Morgan analyst said, "Encouraging new data on IMGN901 in a Phase I multiple myeloma study was reported this weekend at ASCO. Specifically, 13 of 18 patients were evaluable in the combination Phase I study evaluating the combination of IMGN901 with Revlimid and dexamethasone. Objective responses were seen in 8 of the 13 patients evaluated in the study. Most patients had been progressing on 2-3 prior regimens of therapy, which are considered industry standard. Patients were evaluated in three dose levels: 75, 90, and 112 mg/m2 given weekly for 3 weeks in a 4 week cycle. In the two higher doses, dose reduction was required due to peripheral neuropathy. Despite dose reductions, several patients continued to respond while neuropathy improved. We are now more confident that IMGN901 could be an approved oncology drug."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $11.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
- BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)
- Spotify (SPOT) PT Raised to $396 at Rosenblatt
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Morgan JosephSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
